Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?
Option exercise expands executive's long-term equity stake to 612,251 shares, now valued at $18.37 million based on August 7 market close.
Overview
Rickey James Paul, Chief Financial Officer of Braveheart Bio, Inc. (NASDAQ:BRVE), reported an acquisition of 27,777 shares on August 7, 2026. SEC Form 4 filing.
Braveheart Bio engages in the development of therapeutics to treat hypertrophic cardiomyopathy, with its lead product candidate being BHB-1839. The company was founded in 2024 and is headquartered in San Francisco.
Details
Transaction value based on SEC Form 4 weighted average purchase price ($18.00); post-transaction value based on August 07, 2026 market close ($30.00).
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.